Pooja SirDeshpande
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Pooja SirDeshpande has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Biju Gopalkrishnan
1 shared publication- Dharti Dua
Department of Neurology, Ohio State University, Columbus, OH, USA
1 shared publication Hassan Akhtar
Acute Medicine and Endocrinology, University Hospitals of North Midlands NHS Trust, Stafford, GBR
1 shared publicationHemanshi Mistry
1 shared publication- Lakshmi Leishangthem
Department of Neurology/Neuro-ophthalmology, UConn Health, Farmington, CT, USA
1 shared publication - Neel Patel
Department of Public Health, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
1 shared publication
Latest Publications
- Open Access
- 8 December 2025
- Published by Springer Nature in Cureus
- Vol. 17 (12)
Immune Checkpoint Inhibitor-Related Hypophysitis and Pituitary Dysfunction: A Systematic Review of Diagnosis and Management
With an objective to review the clinical presentation, diagnosis, and management of immune checkpoint inhibitor (ICPi)-associated hypophysitis and pituitary dysfunction, we conducted a systematic review of 84 studies (2005-2025) involving 7,259 patients evaluated pituitary immune-related adverse events (irAEs) linked to CTLA-4 inhibitors, programmed cell death protein 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) inhibitors, and combination therapies. Data included ICPi type, demographics, cancer type, treatment duration, imaging, pituitary dysfunction, symptoms and management.
- 8 December 2025
- Published by Springer Nature in Cureus
- Vol. 17 (12)
Open AccessImmune Checkpoint Inhibitor-Related Hypophysitis and Pituitary Dysfunction: A Systematic Review of Diagnosis and Management
With an objective to review the clinical presentation, diagnosis, and management of immune checkpoint inhibitor (ICPi)-associated hypophysitis and pituitary dysfunction, we conducted a systematic review of 84 studies (2005-2025) involving 7,259 patients evaluated pituitary immune-related adverse events (irAEs) linked to CTLA-4 inhibitors, programmed cell death protein 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) inhibitors, and combination therapies. Data included ICPi type, demographics, cancer type, treatment duration, imaging, pituitary dysfunction, symptoms and management.
- 1 June 2019
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 31, 41-50
Thirty-day readmissions in multiple sclerosis: An age and gender-based US national retrospective analysis
- 1 June 2019
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 31, 41-50
Thirty-day readmissions in multiple sclerosis: An age and gender-based US national retrospective analysis
- 1 March 2019
- Published by Elsevier in Journal Of Neuroradiology
- Vol. 46 (2) , 148-154
Dural venous sinus stenting for idiopathic intracranial hypertension: An updated review
- 1 March 2019
- Published by Elsevier in Journal Of Neuroradiology
- Vol. 46 (2) , 148-154
Dural venous sinus stenting for idiopathic intracranial hypertension: An updated review